SunMoon Food CEO Zhang Ye boosts interests
[SINGAPORE] Over the four trading sessions from Jun 13 to 18, institutions were net sellers of Singapore stocks, with net institutional outflow of S$42 million following the S$80 million net outflow in the preceding five sessions. This takes the net institutional outflow for the year to Jun 18 to S$1.88 billion.
Institutional flows
In the four trading sessions, the stocks with the highest net institutional outflow were DBS , Singapore Airlines (SIA), Wilmar International , Singtel , OCBC , Sats , Mapletree Industrial Trust , UOL , Riverstone , and DFI Retail Group .
Meanwhile, Keppel , Singapore Exchange (SGX), ST Engineering , CapitaLand Integrated Commercial Trust , Yangzijiang Shipbuilding , Jardine Matheson , Mapletree Logistics Trust , Rex International , Hongkong Land , and Seatrium led the net institutional inflow over the four sessions.
From a sector perspective, financial services and consumer non-cyclicals experienced the highest net institutional outflow, while industrials and real estate investment trusts (Reits) had the most net institutional inflow.
Singtel leads net institutional inflows in Q2 2025
Institutions were net sellers for much of the second quarter of 2025, but sector flows were mixed, with financial services and Reits seeing the largest outflows, while telecommunications and industrials – led by Singtel, SIA, Keppel, and ST Engineering – recorded notable inflows.
From end-2023 to Jun 18, Singtel led net institutional inflows into the local market with S$1.6 billion, while its Straits Times Index weight rose from 6 per cent to 8 per cent. Its total return ranked it as the second-best performer in the Dow Jones Sector Titans Telecommunication Index.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
Earlier this month, Gerald Wong, founder of financial advisory platform Beansprout, interviewed Singtel's group chief financial officer Arthur Lang to discuss the company's recent momentum. Lang noted that profit growth in FY2025 was driven by strong execution across core business units, with subsidiaries Optus and NCS achieving earnings before interest and taxes expansion of 55 per cent and 39 per cent, respectively.
He also highlighted the 'Singtel28' strategy's focus on lifting business performance by strengthening the company's core connectivity businesses, and scaling growth areas such as IT services and digital infrastructure. For instance, its data centre arm, Nxera, is expanding rapidly with support from a partnership with KKR, enabling regional growth with partial funding from external capital.
Lang also highlighted that longstanding regional partnerships and active capital management to fund growth and boost shareholder returns continue to position Singtel for long-term resilience.
Share buybacks
In the four sessions, 15 primary-listed companies made buybacks with a total consideration of S$61.8 million. DBS, UOB and OCBC again led the consideration tally, collectively buying back S$58.9 million of shares.
On their current buyback mandates, UOB has bought back 0.35 per cent of its outstanding shares, DBS has repurchased 0.22 per cent, and OCBC has bought back 0.06 per cent, as at Jun 18.
Secondary-listed Hongkong Land also continued to conduct share repurchases over the four sessions.
Director transactions
The four trading sessions saw a bit of a pause in director interests and substantial shareholdings filings. There were fewer than 40 filings for 20 primary-listed stocks. Directors or chief executive officers filed six acquisitions and two disposals, while substantial shareholders filed one acquisition and two disposals.
These included director or CEO acquisitions in CosmoSteel , Hyphens Pharma International , Mencast and SunMoon Food Company .
CosmoSteel
On Jun 13, CosmoSteel executive director and CEO Jack Ong acquired two million shares at an average price of S$0.22 each, boosting his direct interest from 17.39 per cent to 18.15 per cent.
On May 15, Evolve Capital Advisory, on behalf of 3HA Capital, announced a voluntary conditional cash offer for all issued and paid-up ordinary shares of CosmoSteel at S$0.20 apiece. The offer has drawn scrutiny from significant shareholders the Ong family, who have requested clarifications. Prior to the development, CosmoSteel's CEO had also raised his direct interest from 14.5 per cent.
SunMoon Food Company
Between Jun 13 and 18, SunMoon Food Company executive director and CEO Zhang Ye acquired 3,099,100 shares at S$0.16 apiece. This increased his total interest from 51.77 per cent to 52.12 per cent.
He has been gradually increasing his total interest from 51.57 per cent May 27, when the group reported its FY2024/2025 (ended Mar 31) results. He was appointed CEO and executive director in December 2018.
The serial entrepreneur also founded Yiguo – China's first fresh food e-commerce platform – and Enmore Group, which is now a leading player in China's bulk chemical services sector.
For FY2024/2025, SunMoon Food Company reported revenue of S$33.83 million, up from S$27.06 million the previous year. The growth was driven by stronger sales of fruits, aquatic foods, and non-hazardous chemical products. The group generated 93 per cent of its revenue for the period from China, with the remainder coming from Asean.
Its gross profit for FY2024/2025 remained steady at S$821,000, though the margin declined to 2.43 per cent from 3.03 per cent in FY2023/2024, due mainly to the clearance of slow-moving inventory sold at minimal or negative margins.
The company said it is working to enhance profitability by expanding its non-hazardous chemical segment through strategic partnerships. It also remains focused on growing cross-border trade – exporting food products from China to South-east Asia, and importing basa fish (a freshwater fish native to South-east Asia) into China.
Hyphens Pharma International
On Jun 16, Hyphens Pharma International non-executive director Tan Kia King acquired 33,600 shares at S$0.30 apiece. This grew his total interest incrementally, from 28.13 per cent to 28.14 per cent.
The open market purchase followed his acquisitions of 100,000 shares in May and 88,000 shares in April, with both transactions at S$0.285 per share.
Appointed in December 2017, Dr Tan brings more than 30 years of medical and leadership experience to the group, including roles as managing director of Westpoint Family Hospital and chairman of Taka Jewellery.
Hyphens Pharma International is headquartered in Singapore with direct operations in Indonesia, Malaysia, the Philippines and Vietnam. Its foundation dates back to 1998, when current chairman and CEO Lim See Wah invested in Pan-Malayan Pharmaceuticals, laying the groundwork for a regional healthcare platform.
Established in the 1940s, Pan-Malayan is Singapore's oldest pharmaceutical wholesaler, with a rich history of supplying clinics, pharmacies, hospitals, nursing homes and trade partners.
In 2002, Lim bought into Hyphens Pharma. The move unlocked Asean expansion and proprietary innovation, including the launch of Ceradan – a therapeutic skincare brand – and strategic research and development with the Agency for Science, Technology and Research.
Hyphens Pharma International listed on the SGX Catalist in 2018. With a growing regional footprint, it continues to champion Asia's role in healthcare innovation.
The group currently comprises five key entities: Hyphens Pharma, DocMed Technology, Ocean Health, Novem and Ardence Pharma. They advance the three core segments of speciality pharmaceuticals; proprietary brands; as well as medical hypermart and digital.
In FY2024 (ended Dec 31), the group reported record revenue of S$195.4 million and a net profit after tax of S$10.9 million. It remains focused on scaling its core segments, with proprietary brands expanding regionally and speciality pharmaceuticals advancing through new launches and exclusive rights.
It also continues to strategically enhance longstanding assets such as Pan-Malayan and online marketplace POM, with a focus on building high-traffic digital platforms to unlock greater value. Part of DocMed Technology, POM is a business-to-business pharmaceutical marketplace that operates in Singapore, Malaysia and Vietnam.
Hyphens Pharma International maintains a market capitalisation of nearly S$100 million, with a return on equity ratio of 15.2 per cent, dividend yield of 4.8 per cent, and price-to-earnings ratio of 9.6 times as at last week.
The counter is also among the 10 SGX-listed healthcare stocks that have booked the highest net institutional inflows in the first half of 2025. In April, Evolve Capital initiated coverage on Hyphens Pharma International with a target price of S$0.365. The advisory platform noted that despite its smaller scale, Hyphens Pharma International maintains decent margins, a net cash position, and consistent revenue growth, making its low valuation unjustified.
While near-term growth may moderate, Evolve Capital expects continued portfolio expansion across the segments of speciality pharmaceuticals and proprietary brands.
Buybacks and director transactions for Jun 19 will be included next week.
The writer is the market strategist at SGX. To read SGX's market research reports, visit sgx.com/research.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
7 hours ago
- Business Times
SunMoon Food CEO Zhang Ye boosts interests
[SINGAPORE] Over the four trading sessions from Jun 13 to 18, institutions were net sellers of Singapore stocks, with net institutional outflow of S$42 million following the S$80 million net outflow in the preceding five sessions. This takes the net institutional outflow for the year to Jun 18 to S$1.88 billion. Institutional flows In the four trading sessions, the stocks with the highest net institutional outflow were DBS , Singapore Airlines (SIA), Wilmar International , Singtel , OCBC , Sats , Mapletree Industrial Trust , UOL , Riverstone , and DFI Retail Group . Meanwhile, Keppel , Singapore Exchange (SGX), ST Engineering , CapitaLand Integrated Commercial Trust , Yangzijiang Shipbuilding , Jardine Matheson , Mapletree Logistics Trust , Rex International , Hongkong Land , and Seatrium led the net institutional inflow over the four sessions. From a sector perspective, financial services and consumer non-cyclicals experienced the highest net institutional outflow, while industrials and real estate investment trusts (Reits) had the most net institutional inflow. Singtel leads net institutional inflows in Q2 2025 Institutions were net sellers for much of the second quarter of 2025, but sector flows were mixed, with financial services and Reits seeing the largest outflows, while telecommunications and industrials – led by Singtel, SIA, Keppel, and ST Engineering – recorded notable inflows. From end-2023 to Jun 18, Singtel led net institutional inflows into the local market with S$1.6 billion, while its Straits Times Index weight rose from 6 per cent to 8 per cent. Its total return ranked it as the second-best performer in the Dow Jones Sector Titans Telecommunication Index. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Earlier this month, Gerald Wong, founder of financial advisory platform Beansprout, interviewed Singtel's group chief financial officer Arthur Lang to discuss the company's recent momentum. Lang noted that profit growth in FY2025 was driven by strong execution across core business units, with subsidiaries Optus and NCS achieving earnings before interest and taxes expansion of 55 per cent and 39 per cent, respectively. He also highlighted the 'Singtel28' strategy's focus on lifting business performance by strengthening the company's core connectivity businesses, and scaling growth areas such as IT services and digital infrastructure. For instance, its data centre arm, Nxera, is expanding rapidly with support from a partnership with KKR, enabling regional growth with partial funding from external capital. Lang also highlighted that longstanding regional partnerships and active capital management to fund growth and boost shareholder returns continue to position Singtel for long-term resilience. Share buybacks In the four sessions, 15 primary-listed companies made buybacks with a total consideration of S$61.8 million. DBS, UOB and OCBC again led the consideration tally, collectively buying back S$58.9 million of shares. On their current buyback mandates, UOB has bought back 0.35 per cent of its outstanding shares, DBS has repurchased 0.22 per cent, and OCBC has bought back 0.06 per cent, as at Jun 18. Secondary-listed Hongkong Land also continued to conduct share repurchases over the four sessions. Director transactions The four trading sessions saw a bit of a pause in director interests and substantial shareholdings filings. There were fewer than 40 filings for 20 primary-listed stocks. Directors or chief executive officers filed six acquisitions and two disposals, while substantial shareholders filed one acquisition and two disposals. These included director or CEO acquisitions in CosmoSteel , Hyphens Pharma International , Mencast and SunMoon Food Company . CosmoSteel On Jun 13, CosmoSteel executive director and CEO Jack Ong acquired two million shares at an average price of S$0.22 each, boosting his direct interest from 17.39 per cent to 18.15 per cent. On May 15, Evolve Capital Advisory, on behalf of 3HA Capital, announced a voluntary conditional cash offer for all issued and paid-up ordinary shares of CosmoSteel at S$0.20 apiece. The offer has drawn scrutiny from significant shareholders the Ong family, who have requested clarifications. Prior to the development, CosmoSteel's CEO had also raised his direct interest from 14.5 per cent. SunMoon Food Company Between Jun 13 and 18, SunMoon Food Company executive director and CEO Zhang Ye acquired 3,099,100 shares at S$0.16 apiece. This increased his total interest from 51.77 per cent to 52.12 per cent. He has been gradually increasing his total interest from 51.57 per cent May 27, when the group reported its FY2024/2025 (ended Mar 31) results. He was appointed CEO and executive director in December 2018. The serial entrepreneur also founded Yiguo – China's first fresh food e-commerce platform – and Enmore Group, which is now a leading player in China's bulk chemical services sector. For FY2024/2025, SunMoon Food Company reported revenue of S$33.83 million, up from S$27.06 million the previous year. The growth was driven by stronger sales of fruits, aquatic foods, and non-hazardous chemical products. The group generated 93 per cent of its revenue for the period from China, with the remainder coming from Asean. Its gross profit for FY2024/2025 remained steady at S$821,000, though the margin declined to 2.43 per cent from 3.03 per cent in FY2023/2024, due mainly to the clearance of slow-moving inventory sold at minimal or negative margins. The company said it is working to enhance profitability by expanding its non-hazardous chemical segment through strategic partnerships. It also remains focused on growing cross-border trade – exporting food products from China to South-east Asia, and importing basa fish (a freshwater fish native to South-east Asia) into China. Hyphens Pharma International On Jun 16, Hyphens Pharma International non-executive director Tan Kia King acquired 33,600 shares at S$0.30 apiece. This grew his total interest incrementally, from 28.13 per cent to 28.14 per cent. The open market purchase followed his acquisitions of 100,000 shares in May and 88,000 shares in April, with both transactions at S$0.285 per share. Appointed in December 2017, Dr Tan brings more than 30 years of medical and leadership experience to the group, including roles as managing director of Westpoint Family Hospital and chairman of Taka Jewellery. Hyphens Pharma International is headquartered in Singapore with direct operations in Indonesia, Malaysia, the Philippines and Vietnam. Its foundation dates back to 1998, when current chairman and CEO Lim See Wah invested in Pan-Malayan Pharmaceuticals, laying the groundwork for a regional healthcare platform. Established in the 1940s, Pan-Malayan is Singapore's oldest pharmaceutical wholesaler, with a rich history of supplying clinics, pharmacies, hospitals, nursing homes and trade partners. In 2002, Lim bought into Hyphens Pharma. The move unlocked Asean expansion and proprietary innovation, including the launch of Ceradan – a therapeutic skincare brand – and strategic research and development with the Agency for Science, Technology and Research. Hyphens Pharma International listed on the SGX Catalist in 2018. With a growing regional footprint, it continues to champion Asia's role in healthcare innovation. The group currently comprises five key entities: Hyphens Pharma, DocMed Technology, Ocean Health, Novem and Ardence Pharma. They advance the three core segments of speciality pharmaceuticals; proprietary brands; as well as medical hypermart and digital. In FY2024 (ended Dec 31), the group reported record revenue of S$195.4 million and a net profit after tax of S$10.9 million. It remains focused on scaling its core segments, with proprietary brands expanding regionally and speciality pharmaceuticals advancing through new launches and exclusive rights. It also continues to strategically enhance longstanding assets such as Pan-Malayan and online marketplace POM, with a focus on building high-traffic digital platforms to unlock greater value. Part of DocMed Technology, POM is a business-to-business pharmaceutical marketplace that operates in Singapore, Malaysia and Vietnam. Hyphens Pharma International maintains a market capitalisation of nearly S$100 million, with a return on equity ratio of 15.2 per cent, dividend yield of 4.8 per cent, and price-to-earnings ratio of 9.6 times as at last week. The counter is also among the 10 SGX-listed healthcare stocks that have booked the highest net institutional inflows in the first half of 2025. In April, Evolve Capital initiated coverage on Hyphens Pharma International with a target price of S$0.365. The advisory platform noted that despite its smaller scale, Hyphens Pharma International maintains decent margins, a net cash position, and consistent revenue growth, making its low valuation unjustified. While near-term growth may moderate, Evolve Capital expects continued portfolio expansion across the segments of speciality pharmaceuticals and proprietary brands. Buybacks and director transactions for Jun 19 will be included next week. The writer is the market strategist at SGX. To read SGX's market research reports, visit
Straits Times
2 days ago
- Straits Times
Singapore shares in the red amid mixed regional showing; STI down 0.3%
SINGAPORE – Shares here declined on June 20 amid concerns over a possible US strike on Iran and the resulting dangers to oil supplies. US equity markets were closed for the Juneteenth holiday overnight, so investors here had to look elsewhere for leads and they didn't like what they saw. While news that the US has delayed any Iranian intervention for two weeks slightly eased tensions, the looming uncertainties still pushed stocks lower. 'The worsening global geopolitical weather keeps investors in a cautious mode, and will likely prevent them from taking too much risk before the weekend,' said Swissquote Bank senior analyst Ipek Ozkardeskaya. The wary mood helped send the Straits Times Index (STI) down 0.3 per cent or 10.75 points to 3,883.43 but gainers beat losers 253 to 203 on solid trade of 1.3 billion securities worth $2.2 billion. The geopolitical uncertainty did not take much of a toll on regional indexes. While Japan's Nikkei 225 and Australia's ASX 200 both slipped 0.2 per cent, the Kospi in South Korea climbed 1.5 per cent, Hong Kong's Hang Seng added 1.3 per cent and Malaysian stocks edged up 0.1 per cent. The Hang Seng Index is now nearly back to its March 2025 highs following the announcement of the trade war truce, noted Morningstar equity market strategist Kai Wang. He added that 'tariffs may again rear its ugly head' in the second half of the year, noting: 'We could see their consequences and whether earnings are under pressure as there are still headwinds to consumer confidence.' The STI's top gainer was conglomerate Jardine Cycle & Carriage, which advanced 3.3 per cent to close at $24.45, while Frasers Logistics and Commercial Trust led the blue-chip losers, falling 2.4 per cent to 81.5 cents. The three local banks were mixed: UOB edged up 0.5 per cent to $34.89; OCBC fell 0.6 per cent to $15.90; and DBS slipped 0.1 per cent to $43.88. THE BUSINESS TIMES Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
2 days ago
- Business Times
Singapore shares end Friday in the red amid mixed regional showing; STI down 0.3%
[SINGAPORE] Local stocks ended lower on Friday (Jun 20), amid a mixed regional performance and growing concerns over a possible US military strike on Iran. The benchmark Straits Times Index (STI) fell 0.3 per cent or 10.75 points to 3,883.43. Across the broader market, advancers beat decliners 253 to 203, with 1.3 billion securities worth S$2.2 billion changing hands. While the news that the US is giving itself two weeks to decide whether to intervene in Iran has slightly eased tensions, the looming uncertainties still pushed US and European equities lower. 'The worsening global geopolitical weather keeps investors in a cautious mode, and will likely prevent them from taking too much risk before the weekend,' said Ipek Ozkardeskaya, senior analyst at Swissquote Bank. Amid this geopolitical uncertainty, key regional indices in Asia-Pacific were mixed. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Japan's Nikkei 225 and Australia's ASX 200 both slipped by 0.2 per cent. Meanwhile, South Korea's Kospi Composite Index climbed 1.5 per cent, Hong Kong's Hang Seng Index rose 1.3 per cent and the Bursa Malaysia Kuala Lumpur Composite Index edged up by 0.1 per cent. The Hang Seng Index is now nearly back to its March 2025 highs following the announcement of the trade war truce, noted Kai Wang, Asia equity market strategist at Morningstar. He highlighted that markets were volatile from January to April due to tariff concerns and suggested that the second half of the year will highly be dependent on tariffs again, but 'tariffs may finally rear its ugly head'. 'We could see their consequences and whether earnings are under pressure as there are still headwinds to consumer confidence,' he added. The top gainer on the STI was Hong Kong-based conglomerate Jardine Cycle & Carriage (C&C), which gained 3.3 per cent or S$0.77 to close at S$24.45. The biggest decliner among the constituents was Frasers Logistics and Commercial Trust (FLCT) , which shed 2.4 per cent or S$0.02 to S$0.815. The three local banks ended mixed. UOB edged up 0.5 per cent or S$0.18 to S$34.89, OCBC fell 0.6 per cent or S$0.09 to S$15.90, while DBS slipped 0.1 per cent or S$0.05 to S$43.88.
